##semicolon##
сўлак бези, сиалоаденит, тизимли касалликлар, Шёгрен синдроми, умумий қон таҳлили, биокимё, коагулограмма, ANA, ANCA, лаборатор диагностика.##submission.citations##
1. Aqrawi L.A., Ivanchenko M., Björk A., et al. Diminished CXCR5 expression in peripheral blood of patients with Sjögren’s syndrome may relate to both genotype and salivary gland homing. Clinical & Experimental Immunology. 2018;192(3):259–270. doi:10.1111/cei.13118.
2. Aqrawi L.A., Ivanchenko M., Björk A., et al. Diminished CXCR5 expression in peripheral blood of patients with Sjögren’s syndrome may relate to both genotype and salivary gland homing. Clinical & Experimental Immunology. 2018;192(3):259–270. doi: 10.1111/cei.13118.
3. Bowman S.J. Primary Sjögren’s syndrome. Lupus. 2018;27(1_suppl):32–35.
4. Brito-Zerón P., Baldini C., Bootsma H., et al. Sjögren syndrome. Nature Reviews Disease Primers. 2016; 2:16047. doi:10.1038/nrdp.2016.47.
5. Lee Y.H., Song G.G. Associations between interleukin-10 polymorphisms and susceptibility to Sjögren’s syndrome: a meta-analysis. International Journal of Immunogenetics. 2025;52(1):24–32. doi: 10.1111/iji.12702.
6. Mariette X., Criswell L.A. Primary Sjögren’s syndrome. New England Journal of Medicine. 2018; 378(10):931–939. doi:10.1056/NEJMcp1702514.
7. Nocturne G., Mariette X. B cells in the pathogenesis of primary Sjögren syndrome. Nature Reviews Rheumatology. 2018;14(3):133–145. doi:10. 1038/nrrheum.2018.1.
8. Ramos-Casals M., Brito-Zerón P., Bombardieri S., et al. EULAR recommendations for the management of Sjögren’s syndrome with topical and systemic therapies. Annals of the Rheumatic Diseases. 2020;79(1):3–18.
9. Shiboski C.H., Shiboski S.C., Seror R., et al. 2016 ACR/EULAR classification criteria for primary Sjögren’s syndrome. Annals of the Rheumatic Diseases. 2017;76(1):9–16.
10. Yura Y., Hamada M. Outline of salivary gland pathogenesis of Sjögren’s syndrome and current therapeutic approaches. International Journal of Molecular Sciences. 2023;24(13):11179. doi:10.33 90/ijms241311179.